It is well known that certain cancers have shown clusteringin educational and socioeconomic groups, but recent comprehensive data on clustering by education are limited. We determined standardized incidence ratios (SIRs), adjusted for several variables, for cancer among men and women in six educational groups based on the Swedish Family-Cancer Database. People were identified with a certain educational background in the census of year 1970; the comparison group was the largest group, those with <9 years of education. Cancers were followed from years 1971 to 1998. Total cancer risks did not differ much, but at individual sites, the trend was significant, either increasing or decreasing over all educational groups (for 27 of 29 male and 28 of 31 female cancers). University graduates had a decreased risk of tobacco-, alcohol-, and genital infection-related cancers, but male graduates had an excess of colon, prostate, squamous cell skin, nervous system cancer, and melanoma. Male graduates showed a low SIR of 0.50 for stomach cancer and a high SIR of 1.89 for melanoma; female graduates showed a low SIR of 0.43 for lung and cervical cancer and a high SIR of 1.57 for melanoma. The overall weighted population attributable fraction for educational level was 13.8% for men and 16.7% for women, and it was highest, >50%, for stomach cancer in both genders and for cervical and anal cancer in women.

Educational level may influence the risk of cancer in many ways. Education is an important attribute guiding the selection of occupation. This, in turn, is a predictive factor for disposable income and many socioeconomic aspects of life, including residential and lifestyle factors. Health-contentious behavior, seeking and affordability of healthy food and participation in health promotional and screening programs, relates to education and socioeconomic factors. Access to and use of healthcare services may help to identify and remove tumors at an early stage before they have become cancers. For a more extensive discussion on social class difference in disease, the reader is referred to reviews on the topic (1, 2). There is ample literature from many developed countries that show consistent patterns of socioeconomic correlates in cancer (3, 4). Lung, stomach, esophageal, and upper aerodigestive tract cancer have been typically more common in deprived social groups, whereas breast and colorectal cancer have had the opposite socioeconomic gradient. The differences have been observed also in comparisons of cancer risks by education level (5, 6, 7, 8). Sweden, as in most Western European countries, has a covering healthcare system, which collects only nominal charges from its users. However, socioeconomic differences have been reported in Sweden for many types of cancer, which are probably mainly because of factors other than the healthcare system (9). Occupational studies on cancer can focus on specific educational backgrounds. A large Nordic study on occupational cancer risks showed that university-educated men with natural science orientation and male physicians experienced a reduced risk of cancer overall but an increased risk at lifestyle-related sites such as colon, prostate, and skin (both melanoma and nonmelanoma skin) cancer (10). The overall cancer risk was increased in the corresponding groups of women, for which breast cancer was the main contributor; however, the data were not corrected for the reproductive history, which is likely to explain at least some of the noted increase.

Because of the limited recent data on cancer risks by educational level, we carried out a follow-up study on men and women for whom an educational level was recorded in the national census of 1970. The analysis was based on the latest update of the Swedish Family-Cancer Database covering 10.2 million people. We hypothesize that educational level influences the risk cancer largely in a similar way as socioeconomic status according to previous studies. PAFs3 are calculated as a measure of the proportion of cancer that can be ascribed to educational factors.

The 2000 update of the nationwide Swedish Family-Cancer Database, covering over 10.2 million individuals and 0.76 million invasive cancers, was used to calculate site-specific cancer risks among men and women (11). The Database included cancer data from the nationwide Swedish Cancer Registry from years 1961 to 1998 (12). The analyses covered all men and women in the Family-Cancer Database, for whom information on a completed education was available in the national census of 1970 in one of the groups shown in Table 1.

The Swedish Cancer Registry is currently using the ICD-O-2/ICD-10 diagnostic coding system but for comparability with the earlier years all codes are translated to the ICD-7 codes. The following ICD-7 codes were pooled: upper aerodigestive cancer (larynx, lip, mouth, and pharynx) and leukemia (leukemia, polycythemia vera, and myelofibrosis). Rectal cancer was separated to anus and mucosal rectum. Skin cancer was squamous cell carcinoma because basal cell carcinoma of the skin has not been registered in the Cancer Registry. Follow-up was started January 1, 1970, and it was terminated on diagnosis of cancer, death, emigration, or the closing date of the study, December 31, 1998. All tumor incidence rates were based on the data in the Family-Cancer Database, and they are essentially similar to rates in the Swedish Cancer Registry. SIRs were calculated as the ratio of observed (O) to expected (E) number of cases. The expected numbers were calculated from 5-year-age-, sex-, tumor type-, 10-year period-, and region- (large cities, north and south Sweden) specific standard incidence rates for all men and women belonging to the largest educational group, <9 years of education, according to the census of year 1970. The data on residential region and socioeconomic status were obtained from a national census. For female cancers, additional adjustments were made for parity and age at first birth, both calculated from the Database (13). Some additional adjustments were done for socioeconomic status- (agriculture, manual workers, blue collar worker, professionals, self-employed, and other) specific standard incidence rates, but these results were not reported. Ninety-five percent confidence intervals were calculated assuming a Poisson distribution (14). Consistency of findings was tested by the χ2-based trend test over all educational groups. PAFs were calculated for all cancer sites based on age-adjusted incidence rates using the formula: (ItIo)/It, where It was the age-adjusted incidence for all men or women with a defined education, and Io was the incidence for the least educated or the university educated, whichever was lower (15). Io was thus the incidence in the group lacking the risk factor for which education was an indicator. The given PAFs only consider the difference between the least and most educated groups. PAF for educational effect over all cancer was calculated from the PAF of all sites by weighting the number of cancers among all educational groups. Correlations between findings for men and women were tested by the Spearman test.

Table 1 shows the study population in different educational groups as defined in the census of year 1970. Over 1.9 million men as well as women were recorded and the largest group, somewhat less than half of all, was those who had a minimal education, <9 years. The difference in male and female education was noted as a larger proportion of university graduates and, particularly doctorates, among men. In the subsequent analysis, we combined university graduate and doctorate because of the small number in the latter group. Men and women accumulated >50 million person-years at risk, and >200,000 cancers were diagnosed for each gender during the period.

SIRs for cancer were calculated for individuals in each of the six educational groups shown in Table 1 (combining university graduates and doctorates). However, because the results were either consistently increasing or decreasing or they remained unchanged by the educational group, we show data only for the least (<9 years) and most educated groups (university educated) and provide additionally results from a trend test across all educational groups as a test for consistency. The data were adjusted for age, period, and region. Table 2 shows SIRs for male cancer at 29 sites by the two educational groups, using the least educated as a reference, SIR of 1.00. The SIR for all cancer among university graduates was 0.93. University graduates had a significantly decreased risk of cancer at 9 sites: upper aerodigestive tract (0.60); esophageal (0.53); stomach (0.50); rectal (0.83); liver (0.68); pancreas (0.83); lung (0.47); kidney (0.79); and bladder (0.85) cancer. They had an increase risk at 7 sites: colon (1.11); breast (1.49); prostate (1.14); testis (1.44); nervous system (1.12) cancer; melanoma (1.89); and squamous cell skin cancer (1.47). A highly significant trend test showed the consistency of the findings across the six educational groups: in all, 27 of 29 trend tests were significant; only endocrine gland and bone tumors and myeloma did not show an educational level gradient. PAFs were calculated, based on the incidence rates, for the difference between the least and the most educated. PAFs with significant differences between the educational levels ranged from 51.2% of stomach and 38% of lung and testicular cancer to small values at sites such as the prostate and bladder. A weighted PAF overall cancer sites was 13.8%.

We adjusted the above data additionally for socioeconomic class in six categories (data not shown). The SIR for all cancer among the least educated did not change and that among university educated changed marginally. However, at individual sites, the changes were larger for the university-educated group: melanoma risk decreased from 1.89 to 1.58, which was the largest changes brought about by the additional adjustment.

Analysis by educational level was conducted for cancer at 31 female sites. The data were adjusted for the same variables as the male data of Table 2 and additionally for parity and age at first childbirth to allow comparison between groups with different obstetric histories. Although the SIR for all cancer was 0.99 among university graduates, as many as 16 sites showed a significant decrease, liver cancer with the lowest SIR of 0.41 and lung and cervical cancer with an SIR of 0.43. These were balanced by three sites that showed an excess: breast cancer, 1.37; melanoma, 1.57; and squamous cell skin cancer, 1.23. The trend test was significant for 28 of 31 of female cancer sites. PAFs for cancer at the stomach, anus, and cervix were >50%. The overall weighted PAF for educational level was 16.7%. When socioeconomic status was introduced as an additional adjustment variable (data not shown), SIRs changed to a limited extent. SIR for melanoma among university educated showed the largest change from 1.57 to 1.41 (Table 3).

We divided the follow-up period into two to examine time trends in risks between educational groups. In Table 4, data are shown for men. Changes at most sites were small, with a few exceptions: among university graduates, male breast cancer was increased only in the latter period, whereas for testicular cancer the trend was opposite. Bone tumors and Hodgkin’s disease were decreased among university graduates only in the latter period, but the significance of this finding remains unclear because it was not reproduced among female graduates (data not shown). The changes among most female sites such as the breast were also small, and we do not tabulate the results. However, among university graduates, the SIR for cervical cancer was 0.33 (n = 77; 95% CI, 0.26–0.41) in years 1970–1984 and 0.61 (n = 85; 95% CI, 0.40–0.76) in years 1985–1998. A similar trend was observed for other genital cancer, with SIRs of 0.44 and 0.64, respectively. An opposite development was noted for lung cancer: female graduates had an SIR of 0.58 (n = 39; 95% CI, 0.41–0.79) in the first period and 0.40 (n = 134; 95% CI, 0.33–0.47) in second period.

Fig. 1 illustrates the uniformity of the findings between men and women for university graduates. All sites were shown that were significant in either gender. Stars above the bars indicate that the SIR was significant. Breast and skin cancer and melanoma were increased for both genders, and upper aerodigestive tract, gastric, liver, lung, kidney, and bladder cancer were decreased for both genders. Among the least educated, the SIR did not correlate between men and women (Spearman correlation coefficient 0.11, when SIRs were calculated by using the whole population as reference). However, SIR correlated among university graduates (Spearman correlation coefficient 0.57, P = 0.003).

This study was based on the Swedish Family-Cancer Database, which has a practically complete coverage of the Swedish population (11). The cancer data originate from the Swedish Cancer Registry and the educational data from the national census of year 1970, conducted by Statistics Sweden. Census forms are individually filled in, and they may contain minor inaccuracies regarding educational level, and these would bias the present results toward null. However, although we cannot exclude the presence of such a bias, the results between men and women showed such consistent patterns that a large bias was unlikely, although female data were adjusted for parity and age at first birth, which may reduce the comparability between genders. Even if any bias between men and women were nonrandom, it is inconceivable that the high correlation between gender SIRs for tumors such as lung cancer and melanoma in Fig. 1 were because of bias: population differences in exposure to the relevant risk factors are well documented. The trend test was significant for 27 of 29 male and 28 of 31 of female cancer sites. Another technical point is that the data were adjusted for period and region. Moreover, because the study covered a large part of the Swedish population, sampling issues appear irrelevant.

The largest educational group, <9 years of school, comprised close to half of the population, and this group served as a reference. For university-educated men and women, tobacco-related sites were in excess, including the lung, upper aerodigestive tract, and for men only, esophagus, of which alcohol contributes to the latter two sites, interactively with tobacco smoking (16). The data are consistent with less than average frequency of tobacco smoking in the educated population (17, 18, 19). For women graduates, lung cancer risk was less in the period 1985–1998 than in period 1970–1984, suggesting that the health education has penetrated best the educated segment of the population. In university-educated men and women, stomach and liver cancers were also decreased, which follows the common socioeconomic gradient (5, 6, 20, 21, 22). A chronic infection by Helicobacter pylori has been identified as the main risk factor of gastric cancer (16). Dietary nitrite, salt, and smoked food are thought to be other risk factors for gastric cancer, and the intake of dietary antioxidants reduces its incidence (23, 24, 25). On the basis of previous studies, low socioeconomic status and large sibship sizes are known risk factors of gastric cancer (26, 27, 28). Cervical and other genital cancers were also decreased in university graduates, but the difference to the least educated decreased toward the end of the follow-up time, suggesting that the beneficial effects of whole population cervical cancer screening programs had equalized the educational differentials in risk (29, 30).

Male university graduates had an excess of cancers of the colon, breast, prostate, testis, nervous system, and skin, including melanoma. The highest SIR of the study was 1.89 for melanoma. Solar irradiation is a risk factor for melanoma and squamous cell skin cancer (31, 32). This is accordance with the known socioeconomic gradient (4). A previous study on socioeconomic factors from Sweden, covering years 1961–1970, found only small differences for melanoma. The present difference, close to 2.0 for men, is probably the result of increasing holiday taking in sunny southern countries (33, 34). For colon cancer, physical inactivity and diet rich in meat and poor of fiber may explain some of the difference in risk between educational backgrounds (35, 36). For prostate and testicular cancer, the absolute differences in SIRs were not large and they were in line with previous studies (4, 5, 6, 37). For prostate cancer, the effect of opportunistic testing cannot be excluded (37). Male and female breast cancer was increased among university graduates, and in men, the effect was limited to the last follow-up period. Much of the increase for women remains unexplained; yet, the data are in agreement with the previous literature (4, 38). Hormonal factors do not offer a simple explanation because endometrial and ovarian cancer did not follow the pattern (39, 40, 41). The low risk of ovarian cancer among university-educated women may be partially because of the protective effects of oral contraceptives (42).

What are the reasons for these systematic differences in cancer risk between educational levels? Considering the earlier literature and the known population distribution of many of the implicated risk factors for cancer occurrence, it is likely that socioeconomic and lifestyle factors weigh heavily on the findings (1, 2). Thus, additional adjustment for socioeconomic factors would appear a priori as an overadjustment. However, our attempt to adjust for socioeconomic factors gave a small overall effect, probably because the socioeconomic and educational classifications are not complementary. Even the narrowest educational group, university graduates, might not fit to a single socioeconomic category “professionals”; some may be classified among “self employed” and “agriculture.” Despite such mixed classification, adjustment for socioeconomic factors reduced markedly some of the highest SIRs such as those for melanoma in the university educated population.

Overall, differences in cancer occurrence between educational groups showed a PAF of 13.8% for men and 16.7% for women. At individual sites, the PAF for stomach cancer was >50% for men and women. For men, tobacco-related sites, the upper aerodigestive tract, esophagus, pancreas, and lung showed PAFs between 20 and 40%, but for women, these sites weighted somewhat less. Prostate and testicular cancer showed PAFs of 3.3 and 38.6%, respectively. Female breast cancer showed a low PAF of 9.6%, but cervical and anal cancers exceeded 50%. At least some risk factors are known for all of the listed neoplasms, except that the variation in testicular cancers cannot be explained. The total PAFs of 13.8 and 16.7% for men and women are relatively large because it has been estimated that no more than 33 and 20% of all cancers arising in men and women in the Nordic populations can be accounted for by the known risk factors (43). In Sweden, smoking habits would account for less than half of these avoidable cases (44). Among other known causes, familial aggregation accounts for <5% of cancer at most sites, and it is highest, 9% for prostate cancer, for which we found a low PAF of 3.3% between educational groups (45, 46). We have carried out a similar exercise on PAFs for socioeconomic factors in the Family-Cancer Database, and some 17% of male and 11% of female cancers can be explained by them (47).

The results show that although the overall risk of cancer does not differ much between people with different educational backgrounds, site-specific risks do differ, largely in directions that can be predicted from the literature on socioeconomic gradients of cancer incidence. The consistency of the gradient suggests that the known and unknown risk factors also change in a uniform way. This should give a handle to resolve the underlying reasons, e.g., why an educational background divides the population in two groups differing 2-fold in their stomach and 1.4-fold in breast cancer risk.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1

The work was supported by the Swedish Cancer Society and the King Gustaf V’s Jubileefund. The Family-Cancer Database was created by linking registers maintained at Statistics Sweden and the Swedish Cancer Registry.

3

The abbreviations used are: PAF, population attributable proportion; ICD, International Classification of Diseases; SIR, standardized incidence ratio; CI, confidence interval.

Fig. 1.

SIR for cancer in male and female university graduates at sites for which the SIR in Tables 2 or 3 is significant for at least one gender. ∗ shows that the 95% CIs for the SIR did not include 1.00.

Fig. 1.

SIR for cancer in male and female university graduates at sites for which the SIR in Tables 2 or 3 is significant for at least one gender. ∗ shows that the 95% CIs for the SIR did not include 1.00.

Close modal
Table 1

Population and cases in male and female educational groups

EducationMenWomen
PopulationPerson-yearsCasesPopulationPerson-yearsCases
Less than 9 years 843,530 21,205,139 122,771 909,615 23,714,365 135,945 
9 years 275,464 7,616,729 12,907 349,815 9,631,969 27,685 
10–11 years 382,542 10,166,507 38,484 422,048 11,520,232 42,735 
12 years 292,865 7,896,530 25,159 122,130 3,342,114 8,786 
College < 3 years 49,956 1,319,173 6258 61,314 1,666,168 6,716 
University graduate 93,015 2,450,640 11,234 63,848 1,740,773 6,971 
Doctorate 7219 185,245 1054 832 21,794 119 
All 1,944,591 50,839,963 217,867 1,929,602 51,637,415 228,957 
EducationMenWomen
PopulationPerson-yearsCasesPopulationPerson-yearsCases
Less than 9 years 843,530 21,205,139 122,771 909,615 23,714,365 135,945 
9 years 275,464 7,616,729 12,907 349,815 9,631,969 27,685 
10–11 years 382,542 10,166,507 38,484 422,048 11,520,232 42,735 
12 years 292,865 7,896,530 25,159 122,130 3,342,114 8,786 
College < 3 years 49,956 1,319,173 6258 61,314 1,666,168 6,716 
University graduate 93,015 2,450,640 11,234 63,848 1,740,773 6,971 
Doctorate 7219 185,245 1054 832 21,794 119 
All 1,944,591 50,839,963 217,867 1,929,602 51,637,415 228,957 
Table 2

SIR and trend for cancer in male educational groupsa

Cancer siteLess than 9 yearsUniversity educatedTrendPAF (%)
ObservedSIR95%CIObservedSIR95%CIχ2P
Upper aerodigestive tract 4,546 1.00 0.97 1.03 334 0.60 0.54 0.67 752.41 0.00 28.1 
Salivary gland 285 1.00 0.89 1.12 35 1.07 0.74 1.49 13.89 0.00 14.5 
Esophagus 1,465 1.00 0.95 1.05 96 0.53 0.43 0.65 239.27 0.00 31.1 
Stomach 6,227 1.00 0.98 1.03 310 0.50 0.45 0.56 1,012.93 0.00 51.2 
Small intestine 625 1.00 0.92 1.08 77 1.11 0.88 1.39 4.01 0.05 0.2 
Colon 8,337 1.00 0.98 1.02 966 1.11 1.04 1.18 20.59 0.00 3.9 
Rectum 6,122 1.00 0.98 1.03 536 0.83 0.76 0.91 70.56 0.00 6.3 
Anus 141 1.00 0.84 1.18 14 0.79 0.43 1.33 13.96 0.00 22.5 
Liver 3,198 1.00 0.97 1.04 234 0.68 0.59 0.77 158.34 0.00 2.7 
Pancreas 3,716 1.00 0.97 1.03 325 0.83 0.74 0.92 98.58 0.00 23.9 
Lung 14,207 1.00 0.98 1.02 794 0.47 0.44 0.50 2,670.32 0.00 37.7 
Breast 168 1.00 0.85 1.16 30 1.49 1.01 2.14 18.93 0.00 2.6 
Prostate 29,152 1.00 0.99 1.01 3,256 1.14 1.10 1.18 266.96 0.00 3.3 
Testis 649 1.00 0.92 1.08 124 1.44 1.20 1.72 349.72 0.00 38.6 
Other male genitals 444 1.00 0.91 1.10 37 0.74 0.52 1.02 12.72 0.00 31.4 
Kidney 4,871 1.00 0.97 1.03 416 0.79 0.71 0.87 36.69 0.00 17.9 
Urinary bladder 8,999 1.00 0.98 1.02 845 0.85 0.79 0.91 12.65 0.00 0.1 
Melanoma 3,713 1.00 0.97 1.03 886 1.89 1.76 2.02 2,047.73 0.00 15.4 
Skin (squamous cell) 4,010 1.00 0.97 1.03 623 1.47 1.35 1.59 396.67 0.00 3.1 
Eye 409 1.00 0.91 1.10 41 0.92 0.66 1.25 20.44 0.00 18.3 
Nervous system 3,738 1.00 0.97 1.03 493 1.12 1.03 1.23 28.48 0.00 15.5 
Thyroid gland 624 1.00 0.92 1.08 75 1.15 0.91 1.44 26.04 0.00 9.5 
Endocrine gland 1,574 1.00 0.95 1.05 212 1.12 0.97 1.28 1.78 0.18 0.9 
Bone 231 1.00 0.88 1.14 18 0.65 0.38 1.02 2.96 0.09 55.7 
Connective tissue 853 1.00 0.93 1.07 102 1.08 0.88 1.31 6.24 0.01 2.0 
Non-Hodgkin’s lymphoma 4,370 1.00 0.97 1.03 499 1.00 0.92 1.09 7.89 0.00 3.1 
Hodgkin’s disease 691 1.00 0.93 1.08 75 0.96 0.76 1.20 35.85 0.00 28.4 
Myeloma 2,019 1.00 0.96 1.04 182 0.89 0.76 1.03 2.10 0.15 15.3 
Leukemia 3,757 1.00 0.97 1.03 393 0.96 0.87 1.06 18.92 0.00 9.6 
All 119,141 1.00 0.99 1.01 12,028 0.93 0.92 0.95 329.41 0.00 13.8b 
Cancer siteLess than 9 yearsUniversity educatedTrendPAF (%)
ObservedSIR95%CIObservedSIR95%CIχ2P
Upper aerodigestive tract 4,546 1.00 0.97 1.03 334 0.60 0.54 0.67 752.41 0.00 28.1 
Salivary gland 285 1.00 0.89 1.12 35 1.07 0.74 1.49 13.89 0.00 14.5 
Esophagus 1,465 1.00 0.95 1.05 96 0.53 0.43 0.65 239.27 0.00 31.1 
Stomach 6,227 1.00 0.98 1.03 310 0.50 0.45 0.56 1,012.93 0.00 51.2 
Small intestine 625 1.00 0.92 1.08 77 1.11 0.88 1.39 4.01 0.05 0.2 
Colon 8,337 1.00 0.98 1.02 966 1.11 1.04 1.18 20.59 0.00 3.9 
Rectum 6,122 1.00 0.98 1.03 536 0.83 0.76 0.91 70.56 0.00 6.3 
Anus 141 1.00 0.84 1.18 14 0.79 0.43 1.33 13.96 0.00 22.5 
Liver 3,198 1.00 0.97 1.04 234 0.68 0.59 0.77 158.34 0.00 2.7 
Pancreas 3,716 1.00 0.97 1.03 325 0.83 0.74 0.92 98.58 0.00 23.9 
Lung 14,207 1.00 0.98 1.02 794 0.47 0.44 0.50 2,670.32 0.00 37.7 
Breast 168 1.00 0.85 1.16 30 1.49 1.01 2.14 18.93 0.00 2.6 
Prostate 29,152 1.00 0.99 1.01 3,256 1.14 1.10 1.18 266.96 0.00 3.3 
Testis 649 1.00 0.92 1.08 124 1.44 1.20 1.72 349.72 0.00 38.6 
Other male genitals 444 1.00 0.91 1.10 37 0.74 0.52 1.02 12.72 0.00 31.4 
Kidney 4,871 1.00 0.97 1.03 416 0.79 0.71 0.87 36.69 0.00 17.9 
Urinary bladder 8,999 1.00 0.98 1.02 845 0.85 0.79 0.91 12.65 0.00 0.1 
Melanoma 3,713 1.00 0.97 1.03 886 1.89 1.76 2.02 2,047.73 0.00 15.4 
Skin (squamous cell) 4,010 1.00 0.97 1.03 623 1.47 1.35 1.59 396.67 0.00 3.1 
Eye 409 1.00 0.91 1.10 41 0.92 0.66 1.25 20.44 0.00 18.3 
Nervous system 3,738 1.00 0.97 1.03 493 1.12 1.03 1.23 28.48 0.00 15.5 
Thyroid gland 624 1.00 0.92 1.08 75 1.15 0.91 1.44 26.04 0.00 9.5 
Endocrine gland 1,574 1.00 0.95 1.05 212 1.12 0.97 1.28 1.78 0.18 0.9 
Bone 231 1.00 0.88 1.14 18 0.65 0.38 1.02 2.96 0.09 55.7 
Connective tissue 853 1.00 0.93 1.07 102 1.08 0.88 1.31 6.24 0.01 2.0 
Non-Hodgkin’s lymphoma 4,370 1.00 0.97 1.03 499 1.00 0.92 1.09 7.89 0.00 3.1 
Hodgkin’s disease 691 1.00 0.93 1.08 75 0.96 0.76 1.20 35.85 0.00 28.4 
Myeloma 2,019 1.00 0.96 1.04 182 0.89 0.76 1.03 2.10 0.15 15.3 
Leukemia 3,757 1.00 0.97 1.03 393 0.96 0.87 1.06 18.92 0.00 9.6 
All 119,141 1.00 0.99 1.01 12,028 0.93 0.92 0.95 329.41 0.00 13.8b 
a

Bold type: 95% CI does not include 1.00, P < 0.05.

b

Weighted PAF of all sites.

Table 3

SIR and trend for cancer in women in educational groupsa

Cancer siteLess than 9 yearsUniversity educatedTrendPAF (%)
ObservedSIR95%CIObservedSIR95%CIχ2P
Upper aerodigestive tract 1,424 1.00 0.95 1.05 54 0.69 0.51 0.89 23.51 0.00 27.7 
Salivary gland 339 1.00 0.90 1.11 15 0.84 0.47 1.39 4.07 0.04 11.1 
Esophagus 518 1.00 0.92 1.09 18 0.80 0.47 1.26 20.50 0.00 13.5 
Stomach 3,736 1.00 0.97 1.03 85 0.57 0.45 0.70 495.94 0.00 52.8 
Small intestine 547 1.00 0.92 1.09 24 0.90 0.57 1.34 0.26 0.61 11.7 
Colon 9,984 1.00 0.98 1.02 370 0.90 0.81 0.99 102.07 0.00 11.9 
Rectum 4,926 1.00 0.97 1.03 194 0.92 0.80 1.06 64.99 0.00 9.8 
Anus 405 1.00 0.90 1.10 0.41 0.18 0.77 100.80 0.00 56.1 
Liver 4,566 1.00 0.97 1.03 93 0.52 0.42 0.64 468.80 0.00 47.2 
Pancreas 3,730 1.00 0.97 1.03 99 0.64 0.52 0.78 113.47 0.00 10.2 
Lung 6,733 1.00 0.98 1.02 173 0.43 0.37 0.50 1,379.10 0.00 32.8 
Breast 35,397 1.00 0.99 1.01 2,972 1.37 1.32 1.42 1,805.33 0.00 9.6 
Cervix 5,442 1.00 0.97 1.03 162 0.43 0.37 0.51 1,793.56 0.00 52.8 
Endometrium 9,188 1.00 0.98 1.02 484 1.04 0.95 1.13 0.16 0.69 6.3 
Uterus 986 1.00 0.94 1.06 45 0.80 0.59 1.08 20.19 0.00 10.1 
Ovary 8,313 1.00 0.98 1.02 380 0.82 0.74 0.90 315.95 0.00 11.1 
Other female genitals 1,171 1.00 0.94 1.06 32 0.58 0.40 0.82 216.32 0.00 10.1 
Kidney 3,919 1.00 0.97 1.03 126 0.75 0.62 0.89 192.32 0.00 25.6 
Urinary bladder 2,965 1.00 0.96 1.04 105 0.80 0.65 0.97 73.75 0.00 10.0 
Melanoma 4,038 1.00 0.97 1.03 443 1.57 1.42 1.72 787.94 0.00 17.8 
Skin (squamous cell) 2,727 1.00 0.96 1.04 132 1.23 1.03 1.46 106.13 0.00 3.8 
Eye 398 1.00 0.90 1.10 22 1.04 0.65 1.57 5.43 0.02 15.3 
Nervous system 4,623 1.00 0.97 1.03 294 1.06 0.95 1.19 12.05 0.00 12.0 
Thyroid gland 1,783 1.00 0.95 1.05 87 0.76 0.61 0.93 123.16 0.00 29.8 
Endocrine gland 4,249 1.00 0.97 1.03 181 0.82 0.70 0.95 106.31 0.00 14.0 
Bone 178 1.00 0.86 1.16 16 1.54 0.88 2.51 3.61 0.06 40.6 
Connective tissue 833 1.00 0.93 1.07 38 0.86 0.61 1.18 6.37 0.01 25.7 
Non-Hodgkin’s lymphoma 3,779 1.00 0.97 1.03 166 0.91 0.78 1.06 68.43 0.00 17.4 
Hodgkin’s disease 460 1.00 0.91 1.10 21 0.79 0.49 1.22 5.48 0.02 57.1 
Myeloma 1,829 1.00 0.95 1.05 53 0.76 0.57 0.99 45.95 0.00 3.9 
Leukemia 3,074 1.00 0.96 1.04 115 0.81 0.67 0.97 35.06 0.00 12.3 
All 132,260 1.00 0.99 1.01 7,008 0.99 0.97 1.02 372.10 0.00 16.7b 
Cancer siteLess than 9 yearsUniversity educatedTrendPAF (%)
ObservedSIR95%CIObservedSIR95%CIχ2P
Upper aerodigestive tract 1,424 1.00 0.95 1.05 54 0.69 0.51 0.89 23.51 0.00 27.7 
Salivary gland 339 1.00 0.90 1.11 15 0.84 0.47 1.39 4.07 0.04 11.1 
Esophagus 518 1.00 0.92 1.09 18 0.80 0.47 1.26 20.50 0.00 13.5 
Stomach 3,736 1.00 0.97 1.03 85 0.57 0.45 0.70 495.94 0.00 52.8 
Small intestine 547 1.00 0.92 1.09 24 0.90 0.57 1.34 0.26 0.61 11.7 
Colon 9,984 1.00 0.98 1.02 370 0.90 0.81 0.99 102.07 0.00 11.9 
Rectum 4,926 1.00 0.97 1.03 194 0.92 0.80 1.06 64.99 0.00 9.8 
Anus 405 1.00 0.90 1.10 0.41 0.18 0.77 100.80 0.00 56.1 
Liver 4,566 1.00 0.97 1.03 93 0.52 0.42 0.64 468.80 0.00 47.2 
Pancreas 3,730 1.00 0.97 1.03 99 0.64 0.52 0.78 113.47 0.00 10.2 
Lung 6,733 1.00 0.98 1.02 173 0.43 0.37 0.50 1,379.10 0.00 32.8 
Breast 35,397 1.00 0.99 1.01 2,972 1.37 1.32 1.42 1,805.33 0.00 9.6 
Cervix 5,442 1.00 0.97 1.03 162 0.43 0.37 0.51 1,793.56 0.00 52.8 
Endometrium 9,188 1.00 0.98 1.02 484 1.04 0.95 1.13 0.16 0.69 6.3 
Uterus 986 1.00 0.94 1.06 45 0.80 0.59 1.08 20.19 0.00 10.1 
Ovary 8,313 1.00 0.98 1.02 380 0.82 0.74 0.90 315.95 0.00 11.1 
Other female genitals 1,171 1.00 0.94 1.06 32 0.58 0.40 0.82 216.32 0.00 10.1 
Kidney 3,919 1.00 0.97 1.03 126 0.75 0.62 0.89 192.32 0.00 25.6 
Urinary bladder 2,965 1.00 0.96 1.04 105 0.80 0.65 0.97 73.75 0.00 10.0 
Melanoma 4,038 1.00 0.97 1.03 443 1.57 1.42 1.72 787.94 0.00 17.8 
Skin (squamous cell) 2,727 1.00 0.96 1.04 132 1.23 1.03 1.46 106.13 0.00 3.8 
Eye 398 1.00 0.90 1.10 22 1.04 0.65 1.57 5.43 0.02 15.3 
Nervous system 4,623 1.00 0.97 1.03 294 1.06 0.95 1.19 12.05 0.00 12.0 
Thyroid gland 1,783 1.00 0.95 1.05 87 0.76 0.61 0.93 123.16 0.00 29.8 
Endocrine gland 4,249 1.00 0.97 1.03 181 0.82 0.70 0.95 106.31 0.00 14.0 
Bone 178 1.00 0.86 1.16 16 1.54 0.88 2.51 3.61 0.06 40.6 
Connective tissue 833 1.00 0.93 1.07 38 0.86 0.61 1.18 6.37 0.01 25.7 
Non-Hodgkin’s lymphoma 3,779 1.00 0.97 1.03 166 0.91 0.78 1.06 68.43 0.00 17.4 
Hodgkin’s disease 460 1.00 0.91 1.10 21 0.79 0.49 1.22 5.48 0.02 57.1 
Myeloma 1,829 1.00 0.95 1.05 53 0.76 0.57 0.99 45.95 0.00 3.9 
Leukemia 3,074 1.00 0.96 1.04 115 0.81 0.67 0.97 35.06 0.00 12.3 
All 132,260 1.00 0.99 1.01 7,008 0.99 0.97 1.02 372.10 0.00 16.7b 
a

Bold type: 95% CI does not include 1.00, P < 0.05.

b

Weighted PAF of all sites.

Table 4

SIR for cancer in male educational groups in different periods

Cancer sitePeriod 1970–1984Period 1985–1998
Less than 9 yearsUniversity educatedLess than 9 yearsUniversity educated
ObservedSIR95%CIObservedSIR95%CIObservedSIR95%CIObservedSIR95%CI
Upper aerodigestive tract 1,910 1.00 0.96 1.05 117 0.59 0.49 0.70 2,636 1.00 0.96 1.04 217 0.61 0.53 0.70 
Salivary gland 131 1.00 0.84 1.19 19 1.40 0.84 2.20 154 1.00 0.85 1.17 16 0.83 0.48 1.36 
Esophagus 445 1.00 0.91 1.10 21 0.44 0.27 0.68 1,020 1.00 0.94 1.06 75 0.56 0.44 0.70 
Stomach 2,517 1.00 0.96 1.04 96 0.44 0.36 0.54 3,710 1.00 0.97 1.03 214 0.54 0.47 0.62 
Small intestine 214 1.00 0.87 1.14 25 1.16 0.75 1.72 411 1.00 0.91 1.10 52 1.09 0.81 1.43 
Colon 2,511 1.00 0.96 1.04 273 1.22 1.08 1.37 5,826 1.00 0.97 1.03 693 1.07 0.99 1.15 
Rectum 1,854 1.00 0.95 1.05 132 0.81 0.68 0.96 4,268 1.00 0.97 1.03 404 0.84 0.76 0.93 
Anus 49 1.00 0.74 1.32 0.52 0.10 1.54 92 1.00 0.81 1.23 11 0.92 0.45 1.65 
Liver 929 1.00 0.94 1.07 69 0.77 0.60 0.98 2,269 1.00 0.96 1.04 1.65 0.64 0.55 0.75 
Pancreas 1,427 1.00 0.95 1.05 103 0.82 0.67 0.99 2,289 1.00 0.96 1.04 222 0.83 0.73 0.95 
Lung 4,942 1.00 0.97 1.03 240 0.48 0.42 0.55 9,265 1.00 0.98 1.02 554 0.46 0.43 0.50 
Breast 55 1.00 0.75 1.30 1.05 0.38 2.30 113 1.00 0.82 1.20 24 1.67 1.07 2.49 
Prostate 5,292 1.00 0.97 1.03 408 1.00 0.91 1.10 23,860 1.00 0.99 1.01 2,848 1.16 1.12 1.21 
Testis 383 1.00 0.90 1.11 82 1.54 1.22 1.91 266 1.00 0.88 1.13 42 1.28 0.92 1.73 
Other male genitals 163 1.00 0.85 1.17 15 0.85 0.47 1.40 281 1.00 0.89 1.12 22 0.68 0.43 1.03 
Kidney 1,956 1.00 0.96 1.05 145 0.77 0.65 0.90 2,915 1.00 0.96 1.04 271 0.80 0.71 0.90 
Urinary bladder 2,659 1.00 0.96 1.04 239 0.94 0.82 1.07 6,340 1.00 0.98 1.02 606 0.82 0.75 0.88 
Melanoma 1,392 1.00 0.95 1.05 313 1.88 1.68 2.10 2,321 1.00 0.96 1.04 573 1.89 1.74 2.05 
Skin (squamous cell) 739 1.00 0.93 1.07 102 1.54 1.26 1.87 3,271 1.00 0.97 1.03 521 1.45 1.33 1.58 
Eye 178 1.00 0.86 1.16 17 1.02 0.59 1.64 231 1.00 0.88 1.14 24 0.86 0.55 1.29 
Nervous system 1,648 1.00 0.95 1.05 206 1.21 1.05 1.38 2,090 1.00 0.96 1.04 287 1.07 0.95 1.20 
Thyroid gland 297 1.00 0.89 1.12 39 1.35 0.96 1.85 327 1.00 0.89 1.11 36 0.99 0.70 1.38 
Endocrine gland 672 1.00 0.93 1.08 80 1.08 0.86 1.35 902 1.00 0.94 1.07 132 1.14 0.95 1.35 
Bone 129 1.00 0.83 1.19 13 0.89 0.47 1.52 102 1.00 0.82 1.21 0.38 0.12 0.89 
Connective tissue 316 1.00 0.89 1.12 39 1.14 0.81 1.57 537 1.00 0.92 1.09 63 1.05 0.80 1.34 
Non-Hodgkin’s lymphoma 1,342 1.00 0.95 1.05 136 0.97 0.81 1.15 3,028 1.00 0.96 1.04 363 1.01 0.91 1.12 
Hodgkin’s disease 411 1.00 0.91 1.10 54 1.20 0.90 1.57 280 1.00 0.89 1.12 21 0.63 0.39 0.97 
Myeloma 636 1.00 0.92 1.08 44 0.79 0.57 1.06 1,383 1.00 0.95 1.05 138 0.93 0.78 1.10 
Leukemia 1,388 1.00 0.95 1.05 133 1.00 0.84 1.18 2,369 1.00 0.96 1.04 260 0.94 0.83 1.07 
All 36,585 1.00 0.99 1.01 3,169 0.91 0.88 0.94 82,556 1.00 0.99 1.01 8,859 0.94 0.92 0.96 
Cancer sitePeriod 1970–1984Period 1985–1998
Less than 9 yearsUniversity educatedLess than 9 yearsUniversity educated
ObservedSIR95%CIObservedSIR95%CIObservedSIR95%CIObservedSIR95%CI
Upper aerodigestive tract 1,910 1.00 0.96 1.05 117 0.59 0.49 0.70 2,636 1.00 0.96 1.04 217 0.61 0.53 0.70 
Salivary gland 131 1.00 0.84 1.19 19 1.40 0.84 2.20 154 1.00 0.85 1.17 16 0.83 0.48 1.36 
Esophagus 445 1.00 0.91 1.10 21 0.44 0.27 0.68 1,020 1.00 0.94 1.06 75 0.56 0.44 0.70 
Stomach 2,517 1.00 0.96 1.04 96 0.44 0.36 0.54 3,710 1.00 0.97 1.03 214 0.54 0.47 0.62 
Small intestine 214 1.00 0.87 1.14 25 1.16 0.75 1.72 411 1.00 0.91 1.10 52 1.09 0.81 1.43 
Colon 2,511 1.00 0.96 1.04 273 1.22 1.08 1.37 5,826 1.00 0.97 1.03 693 1.07 0.99 1.15 
Rectum 1,854 1.00 0.95 1.05 132 0.81 0.68 0.96 4,268 1.00 0.97 1.03 404 0.84 0.76 0.93 
Anus 49 1.00 0.74 1.32 0.52 0.10 1.54 92 1.00 0.81 1.23 11 0.92 0.45 1.65 
Liver 929 1.00 0.94 1.07 69 0.77 0.60 0.98 2,269 1.00 0.96 1.04 1.65 0.64 0.55 0.75 
Pancreas 1,427 1.00 0.95 1.05 103 0.82 0.67 0.99 2,289 1.00 0.96 1.04 222 0.83 0.73 0.95 
Lung 4,942 1.00 0.97 1.03 240 0.48 0.42 0.55 9,265 1.00 0.98 1.02 554 0.46 0.43 0.50 
Breast 55 1.00 0.75 1.30 1.05 0.38 2.30 113 1.00 0.82 1.20 24 1.67 1.07 2.49 
Prostate 5,292 1.00 0.97 1.03 408 1.00 0.91 1.10 23,860 1.00 0.99 1.01 2,848 1.16 1.12 1.21 
Testis 383 1.00 0.90 1.11 82 1.54 1.22 1.91 266 1.00 0.88 1.13 42 1.28 0.92 1.73 
Other male genitals 163 1.00 0.85 1.17 15 0.85 0.47 1.40 281 1.00 0.89 1.12 22 0.68 0.43 1.03 
Kidney 1,956 1.00 0.96 1.05 145 0.77 0.65 0.90 2,915 1.00 0.96 1.04 271 0.80 0.71 0.90 
Urinary bladder 2,659 1.00 0.96 1.04 239 0.94 0.82 1.07 6,340 1.00 0.98 1.02 606 0.82 0.75 0.88 
Melanoma 1,392 1.00 0.95 1.05 313 1.88 1.68 2.10 2,321 1.00 0.96 1.04 573 1.89 1.74 2.05 
Skin (squamous cell) 739 1.00 0.93 1.07 102 1.54 1.26 1.87 3,271 1.00 0.97 1.03 521 1.45 1.33 1.58 
Eye 178 1.00 0.86 1.16 17 1.02 0.59 1.64 231 1.00 0.88 1.14 24 0.86 0.55 1.29 
Nervous system 1,648 1.00 0.95 1.05 206 1.21 1.05 1.38 2,090 1.00 0.96 1.04 287 1.07 0.95 1.20 
Thyroid gland 297 1.00 0.89 1.12 39 1.35 0.96 1.85 327 1.00 0.89 1.11 36 0.99 0.70 1.38 
Endocrine gland 672 1.00 0.93 1.08 80 1.08 0.86 1.35 902 1.00 0.94 1.07 132 1.14 0.95 1.35 
Bone 129 1.00 0.83 1.19 13 0.89 0.47 1.52 102 1.00 0.82 1.21 0.38 0.12 0.89 
Connective tissue 316 1.00 0.89 1.12 39 1.14 0.81 1.57 537 1.00 0.92 1.09 63 1.05 0.80 1.34 
Non-Hodgkin’s lymphoma 1,342 1.00 0.95 1.05 136 0.97 0.81 1.15 3,028 1.00 0.96 1.04 363 1.01 0.91 1.12 
Hodgkin’s disease 411 1.00 0.91 1.10 54 1.20 0.90 1.57 280 1.00 0.89 1.12 21 0.63 0.39 0.97 
Myeloma 636 1.00 0.92 1.08 44 0.79 0.57 1.06 1,383 1.00 0.95 1.05 138 0.93 0.78 1.10 
Leukemia 1,388 1.00 0.95 1.05 133 1.00 0.84 1.18 2,369 1.00 0.96 1.04 260 0.94 0.83 1.07 
All 36,585 1.00 0.99 1.01 3,169 0.91 0.88 0.94 82,556 1.00 0.99 1.01 8,859 0.94 0.92 0.96 

Bold type: 95% CI not include 1.00.

1
Marmot M. G., Kogevinas M., Elston M. A. Social/economic status and disease.
Annu. Rev. Public Health
,
8
:
111
-135,  
1987
.
2
Berkman L. F., Macintyre S. The measurement of social class in health studies: old measures and new formulations.
IARC Sci. Publ.
,
138
:
51
-64, IARC Lyon, France  
1997
.
3
Van Loon A. J., Brug J., Goldbohm R. A., Van Den Brandt P. A. Differences in cancer incidence and mortality among socioeconomic groups.
Scand. J. Soc. Med.
,
23
:
110
-120,  
1995
.
4
IARC Social inequalities and cancer.
IARC Sci. Publ.
,
138
: IARC Lyon, France  
1997
.
5
Faggiano F., Zanetti R., Costa G. Cancer risk and social inequalities in Italy.
J. Epidemiol. Commun. Health
,
48
:
447
-452,  
1994
.
6
Faggiano F., Lemma P., Costa G., Gnavi R., Pagnanelli F. Cancer mortality by educational level in Italy.
Cancer Causes Control
,
6
:
311
-320,  
1995
.
7
Mackenbach J. P., Kunst A. E., Groenhof F., Borgan J. K., Costa G., Faggiano F., Jozan P., Leinsalu M., Martikainen P., Rychtarikova J., Valkonen T. Socioeconomic inequalities in mortality among women and among men: an international study.
Am. J. Public Health
,
89
:
1800
-1806,  
1999
.
8
Steenland K., Henley J., Thun M. All-cause and cause-specific death rates by educational status for two million people in two American Cancer Society cohorts, 1959–1996.
Am. J. Epidemiol.
,
156
:
11
-21,  
2002
.
9
Vagero D., Persson G. Occurrence of cancer in socioeconomic groups in Sweden. An analysis based on the Swedish Cancer Environment Registry.
Scand. J. Soc. Med.
,
14
:
151
-160,  
1986
.
10
Andersen A., Barlow L., Engeland A., Kjärheim K., Lynge E., Pukkala E. Work-related cancer in the Nordic countries.
Scand. J. Work Environ. Health
,
25
:
1
-116,  
1999
.
11
Hemminki K., Li X., Plna K., Granström C., Vaittinen P. The nation-wide Swedish Family-Cancer Database: updated structure and familial rates.
Acta Oncol.
,
40
:
772
-777,  
2001
.
12
Hemminki K., Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiological study from Sweden.
Int. J. Cancer
,
94
:
444
-448,  
2001
.
13
Hemminki K., Mutanen P. Birth order, family size, and the risk of cancer in young and middle-aged adults.
Br. J. Cancer
,
84
:
1466
-1471,  
2001
.
14
Esteve J., Benhamou E., Raymond L. Statistical methods in cancer research.
IARC Sci. Publ.
, IARC Lyon, France  
1994
.
15
dos Santos Silva I. .
Cancer epidemiology: principles and methods
, IARC Lyon  
1999
.
16
Hamilton S. Aaltonen L. eds. .
Tumours of the digestive system. World Health Organization Classification of Tumours.
, IARC Lyon  
2000
.
17
Ans Nicolaides-Bouman N., Forey B., Lee P. .
International smoking statistics: a collection of historical data from 22 economically developed countries
, Oxford University Press London  
1993
.
18
Nordlund L., Carstensen J., Pershagen G. Cancer incidence in female smokers: a 26-year follow-up.
Int. J. Cancer
,
73
:
625
-628,  
1997
.
19
Li X., Mutanen P., Hemminki K. Gender-specific incidence trends in lung cancer by histological type in Sweden, 1958–1996.
Eur. J. Cancer Prev.
,
10
:
227
-235,  
2001
.
20
Li X., Hemminki K. Cancer risks in women who had children with different partners from the Swedish Family-Cancer Database.
Eur. J. Cancer Prev.
,
11
:
433
-438,  
2002
.
21
Hemminki K., Jiang Y. Cancer risks among long-standing spouses.
Br. J. Cancer
,
86
:
1737
-1740,  
2002
.
22
Hemminki K., Jiang Y. Life style and cancer: effect of divorce.
Int. J. Cancer
,
98
:
316
-319,  
2002
.
23
Kumar V., Cotran R., Robbins S. .
Basic Pathology.
, W. B. Saunders Philadelphia  
1997
.
24
Palli D., Caporaso N. E., Shiao Y. H., Saieva C., Amorosi A., Masala G., Rice J. M., Fraumeni J. F., Jr. Diet, helicobacter pylori, and p53 mutations in gastric cancer: a molecular epidemiology study in Italy.
Cancer Epidemiol. Biomark. Prev.
,
6
:
1065
-1069,  
1997
.
25
Ekstrom A. M., Serafini M., Nyren O., Hansson L. E., Ye W., Wolk A. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden.
Int. J. Cancer
,
87
:
133
-140,  
2000
.
26
La Vecchia C., Ferraroni M., D’Avanzo B., Franceschi S., Decarli A., Baron J. A. Number of siblings and subsequent gastric cancer risk.
Eur. J. Cancer Prev.
,
4
:
69
-72,  
1995
.
27
La Vecchia C., D’Avanzo B., Negri E., Decarli A., Benichou J. Attributable risks for stomach cancer in northern Italy.
Int. J. Cancer
,
60
:
748
-752,  
1995
.
28
Goodman K., Correa P. Transmission of Helicobacter pylori among siblings.
Lancet
,
355
:
358
-362,  
2000
.
29
Bergstrom R., Sparen P., Adami H-O. Trends in cancer of the cervix uteri in Sweden following cytological screening.
Br. J. Cancer
,
81
:
159
-166,  
1999
.
30
Hemminki K., Li X., Mutanen P. Age-incidence relationships and time trends in cervical cancer in Sweden.
Eur. J. Epidemiol.
,
17
:
323
-328,  
2001
.
31
Elwood J. Melanoma and ultraviolet radiation.
Clin. Dermatol.
,
10
:
41
-50,  
1992
.
32
English D., Armstrong B., Kricker A., Fleming C. Sunlight and cancer.
Cancer Causes Control
,
8
:
271
-283,  
1997
.
33
Boldeman C., Branstrom R., Dal H., Kristjansson S., Rodvall Y., Jansson B., Ullen H. Tanning habits and sunburn in a Swedish population age 13–50 years.
Eur. J. Cancer
,
37
:
2441
-2448,  
2001
.
34
Hemminki K., Zhang H., Czene K. Incidence trends and familial risks in invasive and in situ cutaneous melanoma by sun exposed body sites.
Int. J. Cancer
,
104
:
764
-771,  
2003
.
35
World Cancer Res. Fund .
Food, Nutrition and the Prevention of Cancer: a global perspective
, American Institute of Cancer Res. Washington, DC  
1997
.
36
Potter J. Colorectal cancer: molecules and populations.
J. Natl. Cancer Inst. (Bethesda)
,
91
:
916
-932,  
1999
.
37
Pukkala E., Weiderpass E. Socio-economic differences in incidence rates of cancer of the male genital organs in Finland, 1971–95.
Int. J. Cancer
,
102
:
643
-648,  
2001
.
38
Pukkala E., Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971–1995).
Int. J. Cancer
,
81
:
56
-61,  
1999
.
39
Hulka B. Epidemiologic analysis of breast and gynecologic cancers.
Prog. Clin. Biol. Res.
,
396
:
17
-29,  
1997
.
40
Persson I., Weiderpass E., Bergkvist L., Bergstrom R., Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.
Cancer Causes Control
,
10
:
253
-260,  
1999
.
41
Akhmedkhanov A., Zeleniuch-Jacquotte A., Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives.
Ann. N. Y. Acad. Sci.
,
943
:
296
-315,  
2001
.
42
Riman T., Dickman P. W., Nilsson S., Correia N., Nordlinder H., Magnusson C. M., Persson I. R. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study.
Am. J. Epidemiol.
,
156
:
363
-373,  
2002
.
43
Olsen J. H., Andersen A., Dreyer L., Pukkala E., Tryggvadottir L., Gerhardsson de Verdier M., Winther J. F. Summary of avoidable cancers in the Nordic countries.
APMIS Suppl.
,
76
:
141
-146,  
1997
.
44
Simonato L., Agudo A., Ahrens W., Benhamou E., Benhamou S., Boffetta P., Brennan P., Darby S. C., Forastiere F., Fortes C., Gaborieau V., Gerken M., Gonzales C. A., Jockel K. H., Kreuzer M., Merletti F., Nyberg F., Pershagen G., Pohlabeln H., Rosch F., Whitley E., Wichmann H. E., Zambon P. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity.
Int. J. Cancer
,
91
:
876
-887,  
2001
.
45
Hemminki K., Czene K. Attributable risks of familial cancer from the Family-Cancer Database.
Cancer Epidemiol. Biomark. Prev.
,
11
:
1638
-1644,  
2002
.
46
Hemminki K., Czene K. Age specific and attributable risks of familial prostate carcinoma from the Family-Cancer Database.
Cancer (Phila.)
,
95
:
1346
-1353,  
2002
.
47
Hemminki K., Zhang H., Czene K. Socioeconomic factors in cancer in Sweden.
Int. J. Cancer.
,
105
:
692
-700,  
2003
.